An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas)

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: January 24, 2011
Last updated: May 4, 2016
Last verified: May 2016
This observational, multi-center, open-label study will evaluate the prognostic factors of long-term-response and the safety of Pegasys (peginterferon alfa-2a) in patients with HbeAg-negative chronic hepatitis B. Data will be collected for 96 weeks.

Hepatitis B, Chronic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prognostic Factors of Long-term Response to Treatment With Pegylated Interferon Alfa-2a in Patients With HbeAg-negative Chronic Hepatitis B. (Perseas)

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of patients with combined (virological and biochemical) response [ Time Frame: 48 weeks after end of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Normalization of serum alanine aminotransferase [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Safety (Incidence of adverse events) [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 107
Study Start Date: May 2009
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with chronic hepatitis B on treatment with Pegasys

Inclusion Criteria:

  • Adult patients, >/=18 years of age
  • Diagnosis of HBeAg-negative chronic hepatitis B with compensated hepatic disease, virus multiplication, raised alanine amino transferase results and/or fibrosis

Exclusion Criteria:

  • Co-infection with hepatitis A, C or D
  • Co-infection with human immunodeficiency virus (HIV)
  • Severe hepatic dysfunction or decompensated liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01283074

Alexandroupolis, Greece, 68100
Athens, Greece, 124 61
Athens, Greece, 10676
Athens, Greece, 115 27
Athens, Greece, 11521
Athens, Greece, 11527
Athens, Greece, 11528
Larissa, Greece, 41 110
Patra, Greece, 265 04
Piraeus, Greece, 18454
Piraeus, Greece, 18536
Rhodes, Greece, 85100
Thessaloniki, Greece, 546 42
Thessaloniki, Greece, 54636
Thessaloniki, Greece, 56429
Thessaloniki, Greece, 57010
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche Identifier: NCT01283074     History of Changes
Other Study ID Numbers: ML22016 
Study First Received: January 24, 2011
Last Updated: May 4, 2016
Health Authority: Greece: Ministry of Health and Welfare

Additional relevant MeSH terms:
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
DNA Virus Infections
Digestive System Diseases
Enterovirus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases processed this record on May 24, 2016